



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Wands *et al.*

SERIAL NUMBER: 09/903,199

EXAMINER: Not Yet Assigned

FILING DATE: July 11, 2001

ART UNIT: 1642

FOR: DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS

October 3, 2001  
Boston, Massachusetts

Assistant Commissioner for Patents  
Washington, D.C. 20231

**RESPONSE TO NOTICE TO COMPLY WITH  
SEQUENCE LISTING REQUIREMENTS**

In response to the Notice to Comply with Sequence Listing Requirements, mailed August 7, 2001, in the above-identified application, Applicants submit a substitute paper copy, and a computer readable form of the Sequence Listing. Also enclosed are a Preliminary Amendment, a Statement in Support of Computer Readable Form Submission, and a copy of the Notice to Comply with Requirements. Please charge any additional fees that may be due, or credit any overpayment to Deposit Account No. 50-0311, Reference No. 21486-032DIV4.

Respectfully submitted,

Ingrid A. Beattie, Reg. No. 42,306  
David E. Johnson, Reg. No. 41,874  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

TECH CENTER 1600/2900

OCT 09 2001

RECEIVED

Express Mail Label No.: E186224606745

Date of Deposit: OCTOBER 3, 2001

Attorney Docket No. 21486-032DIV4



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Wands, et al.

SERIAL NUMBER: 09/903,199

EXAMINER: Not yet assigned

FILING DATE: July 11, 2001

ART UNIT: 1642

FOR: DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS

October 1, 2001

Boston, Massachusetts


Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
OCT 09 2001  
TECH CENTER 1600/2900

STATEMENT IN SUPPORT OF COMPUTER READABLE  
FORM SUBMISSION UNDER 37 C.F.R. § 1.821(f)

I hereby state that the content of the paper and computer readable forms of the Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. § 1.821(c) and 1.821(e), respectively, are the same.


Respectfully submitted,

  
Sean M. Coughlin  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Express Mail Label No.: EL562266067US

Date of Deposit: October 3, 2001

Attorney Docket No. 21486-032DIV4



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Wands *et al.*

SERIAL NUMBER: 09/903,199

EXAMINER: Not Yet Assigned

FILING DATE: July 11, 2001

ART UNIT: 1642

FOR: DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS

October 3, 2001  
Boston, Massachusetts

TECH CENTER 1600/2900

OCT 09 2001

RECEIVED

Assistant Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER

Sir:

Transmitted herewith for filing in the above-identified application are the following documents:

- ☒ Response to Notice to Comply with Sequence Listing Requirements (1 pg.);
- ☒ Preliminary Amendment (2 pgs.);
- ☒ Sequence Listing (15 pgs.);
- ☒ One Diskette;
- ☒ Statement in Support of Computer Readable Form Submission (1 pg.);
- ☒ Copy of Notice to Comply with Requirements (2 pgs.); and
- ☒ Return Postcard.


If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at 617-542-6000, Boston, Massachusetts.

APPLICANTS: Wands, et al.  
U.S.S.N.: 09/903,199

Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 21486-032DIV4). A duplicate copy of this Petition is enclosed.

Respectfully submitted,


October 3, 2001

  
Ingrid A. Beattie, Reg. No. 42,306  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov



APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/903,199	07/11/2001	Jack R. Wands	21486-032DIV4

LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, MA 02111

RECEIVED  
OCT 09 2001  
TECH CENTER 1600/2900

CONFIRMATION NO. 1568

## FORMALITIES LETTER



\*OC00000006393865\*

Date Mailed: 08/07/2001

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE